Home » Stocks » DRNA

Dicerna Pharmaceuticals, Inc. (DRNA)

Stock Price: $28.31 USD 0.29 (1.03%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
After-hours: $27.00 -1.31 (-4.63%) Feb 25, 7:38 PM
Market Cap 2.12B
Revenue (ttm) 130.43M
Net Income (ttm) -115.83M
Shares Out 74.52M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE 28.49
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $28.31
Previous Close $28.02
Change ($) 0.29
Change (%) 1.03%
Day's Open 28.13
Day's Range 27.72 - 29.45
Day's Volume 1,271,335
52-Week Range 11.75 - 29.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 weeks ago

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) initiates patient dosing in Phase 1 PHYOX 4 trial evaluating its lead candidate, nedosiran, to treat primary hyperoxaluria, a rare condition characte...

Business Wire - 2 weeks ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced initiation of patient dosing in its PHYOX™4 clinical trial to assess nedosiran for the treatment of primary hyperoxaluria type 3.

Business Wire - 1 month ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14.

Business Wire - 1 month ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies.

Business Wire - 1 month ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the Company approved the grant of inducement stock options of common stock and restricted stock units among three new employees.

Business Wire - 1 month ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today announced the enrollment completion of the PHYOX™2 pivotal trial of nedosiran for the treatment of primary hyperoxaluria.

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Dicerna (DRNA) stock based on the movements in the options market lately.

Seeking Alpha - 2 months ago

Dicerna is right behind Alnylam in the RNAi space. Its lead candidate is nedosiran targeting primary hyperoxaluria.

Business Wire - 2 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among six new employees.

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV).

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced FDA acceptance of the IND Application filed by Lilly for LY3561774, clinical-stage candidate to emerge from their collaboration.

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Douglas M. Fambrough, Ph.D., president and CEO, will be participating in fireside chats at two upcoming investor conferences.

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present an update on the Company's early-stage development of extrahepatic RNAi therapeutics at TIDES Europe 2020.

Insider Monkey - 3 months ago

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete ...

Seeking Alpha - 3 months ago

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the third quarter ended Sep. 30, 2020.

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among nine new employees.

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna will present updated data related to RG6346, an RNAi investigational therapy, at The Liver Meeting® Digital Experience™ 2020.

Business Wire - 3 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it will release its Q3 2020 financial results and will provide a general business update on Thursday, Nov. 5.

Zacks Investment Research - 3 months ago

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insider Monkey - 3 months ago

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry exp...

Other stocks mentioned: BPMC, ANAB, QURE, SPRO
Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive new interim data from its ongoing PHYOX3 open-label trial of nedosiran, an investigational therapy for PH1, PH2 and PH3.

Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20.

Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that clinical data on nedosiran, an investigational candidate for the treatment of PH, will be presented at ASN Kidney Week 2020.

Business Wire - 4 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that ...

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the hiring of Ling Zeng, Esq.

Seeking Alpha - 5 months ago

Dicerna develops RNAi therapies. Several large-cap pharma companies are collaborators.

Business Wire - 5 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company will be participating in four virtual investor conferences in September.

Seeking Alpha - 6 months ago

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -304.76% and -46.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for...

Business Wire - 6 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna presents positive clinical data for investigational treatments RG6346 for chronic HBV and Nedosiran for PH and preclinical data in new tissues

Business Wire - 6 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the second quarter ended June 30, 2020.

Business Wire - 6 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the appointment of Shreeram Aradhye, M.D.

Zacks Investment Research - 6 months ago

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it will release its Q2 2020 financial results before market open on Thurs.

The Motley Fool - 7 months ago

Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.

Other stocks mentioned: FATE
Seeking Alpha - 9 months ago

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Douglas Fambrough on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -210.71% and -42.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead fo...

The Motley Fool - 10 months ago

These development-stage drug companies are well positioned for success, even amid the current market uncertainty.

Other stocks mentioned: AXSM
GuruFocus - 10 months ago

Adopting the theory that two heads are better than one, a pair of former biotech rivals are teaming up to take on a third company that has a head start in the search for a treatment for a gene...

Other stocks mentioned: ALNY
Investors Business Daily - 11 months ago

Dicerna Pharmaceuticals sees its Relative Strength Rating reach the 80-plus level. The post Stocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals appeared first on Investor's Bus...

Seeking Alpha - 11 months ago

Dicerna Pharmaceuticals' (DRNA) CEO Doug Fambrough on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -625.00% and -73.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead...

Investopedia - 1 year ago

Bullish chat patterns on small- and micro-cap stocks across the U.S. suggest that we could be in the early stages of a long-term uptrend.

Other stocks mentioned: IWC, ONTO
The Motley Fool - 1 year ago

These two promising RNAi drug developers are trading at hefty premiums going into 2020.

Other stocks mentioned: ARWR
The Motley Fool - 1 year ago

What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.

Zacks Investment Research - 1 year ago

The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.

Investors Business Daily - 1 year ago

Shares of Alnylam Pharmaceuticals tried to rally Tuesday after the biotech company's RNAi technology succeeded in a kidney disease. But Alnylam has some rivals waiting in the winds.

Other stocks mentioned: ALNY
Seeking Alpha - 1 year ago

Dicerna Pharmaceuticals: A Solid Pick For 2020

Zacks Investment Research - 1 year ago

Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

About DRNA

Dicerna Pharmaceuticals, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 2014
CEO
Douglas Fambrough
Employees
187
Stock Exchange
NASDAQ
Ticker Symbol
DRNA
Full Company Profile

Financial Performance

In 2019, DRNA's revenue was $23.90 million, an increase of 287.05% compared to the previous year's $6.18 million. Losses were -$120.46 million, 35.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for DRNA stock is "Strong Buy." The 12-month stock price forecast is 34.63, which is an increase of 22.32% from the latest price.

Price Target
$34.63
(22.32% upside)
Analyst Consensus: Strong Buy